Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026
Novo presented COMPETE SWITCH CV real-world data at EASD 2026. Adults with type 2 diabetes who escalated from Ozempic 1 mg to 2 mg were associated with a 6% lower MACE risk than those who switched to Mounjaro.
AbbVie Valkai AI Partnership Deploys Purpose-Built AI Across Targeted Clinical Development Areas
AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion
Novo Nordisk HRS-1596 is the focus of a new exclusive license with Hengrui Pharma worth up to $2.6 billion, including $300 million upfront. The phase 1-ready GLP-1/GIP dual agonist has potential for once-weekly oral dosing.
Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement
Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.
AbbVie JUVMO (Tavapadon) Wins FDA Approval as First Selective D1/D5 Receptor Agonist for Parkinson’s Disease
AbbVie JUVMO (tavapadon) has received FDA approval as the first selective D1/D5 receptor agonist for adults with Parkinson’s disease. AbbVie expects U.S. availability in October 2026.
Merck Ifinatamab Deruxtecan BLA Withdrawn in Previously Treated ES-SCLC
Merck and Daiichi Sankyo have voluntarily withdrawn the U.S. Biologics License Application for ifinatamab deruxtecan in certain patients with previously treated extensive-stage small cell lung cancer after discussions with the FDA indicated that the submitted data did not meet the requirements for accelerated approval.
Eli Lilly Olumiant Alopecia Areata Treatment Approved by FDA for Pediatric Patients 12 and Older
Lilly Olumiant Alopecia Areata has received FDA approval for pediatric patients 12 and older, expanding treatment access based on Phase 3 BRAVE-AA-PEDS trial results showing substantial scalp hair regrowth in adolescents with severe alopecia areata.
Lilly Onswik FDA Approval: Eli Lilly’s Weekly Basal Insulin Clears FDA for Type 2 Diabetes
The FDA has approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Backed by the QWINT Phase 3 program spanning over 3,400 patients, Onswik becomes Lilly’s fourth global approval for the weekly insulin, expected to launch via the KwikPen in the coming months.
J&J TECVAYLI DARZALEX FASPRO Survival Data Redefine Long-Term Outlook in Early Multiple Myeloma Relapse
New MajesTEC-3 modeling from Johnson & Johnson finds that TECVAYLI plus DARZALEX FASPRO, used as early as second line, could give roughly 87% of relapsed/refractory multiple myeloma patients a mortality risk and life expectancy close to the general population, driven by a 90% drop in disease-progression risk versus standard of care.
Johnson & Johnson CAPLYTA Bipolar Mania Study Shows Significant and Rapid Improvement
Johnson & Johnson has reported pivotal Phase 3 findings for CAPLYTA (lumateperone) in bipolar mania, with the study showing significant and rapid improvement in manic symptoms.